Participants entering a combination phase may be a selected subset of those who began a study. That selection is central to interpreting this trial. Primary study
Study outline
Twenty-three men began hCG pretreatment. Eighteen with normalized testosterone but persistent azoospermia entered the subsequent single-arm combination phase with corifollitropin alfa, a long-acting FSH analog. Fourteen of those 18 reached the prespecified sperm-concentration threshold, and testicular volume increased. Primary report
Our appraisal: retain both denominators
The combination-phase response fraction describes men who met its entry conditions. It should not be presented as the response of every initially screened patient or every man with hypogonadotropic hypogonadism. The reasons participants did not enter that phase matter to applicability.
Pretreatment also separates testosterone normalization from sperm production. A normal blood hormone result did not mean the reproductive endpoint had already been achieved. The study's design makes that distinction visible.
Testicular volume was the primary efficacy endpoint, while the sperm threshold was a key secondary endpoint. Both are relevant, but neither is a live-birth measure. Their hierarchy should not be rearranged after seeing the results.
Because there was no concurrent comparison arm, the trial does not establish superiority or equivalence to shorter-acting FSH preparations. Reduced administration frequency, if relevant to convenience, is a different claim from improved fertility efficacy.
The report contributes evidence about a specific long-acting analog used in a defined sequence. It cannot be transferred to hMG or an unspecified FSH product solely because they share an endocrine target. Full review should examine pretreatment exclusions, missing data, antibody-assay methods, and the precision of the reproductive outcomes before publication.
Frequently asked questions
How many men began pretreatment?
Twenty-three.
How many entered the combination phase?
Eighteen.
How many combination-phase participants reached the sperm threshold?
Fourteen.
Did normal testosterone guarantee sperm production?
No; persistent azoospermia was part of combination-phase entry.
Was the trial comparative?
No, it was single-arm.
Is testicular growth a live-birth outcome?
No.
What should not be inferred?
Superiority to other FSH products from this design alone.